For over 60 years, the dopaminergic hypothesis of schizophrenia has formed the basis of the schizophrenia treatment paradigm.

An FDA-approved synthetic THC significantly reduces agitation in Alzheimer's patients, improving treatment outcomes and ...

Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's ...

Recent research is painting a clearer picture of the link between the use of clozapine for schizophrenia and respiratory ...

Variations in the use of antidementia and antipsychotic drugs for nursing home residents with dementia across the United ...

Christopoulos, Dean of the Faculty of Pharmaceutical Sciences at Monash University, is at the centre of a significant ...

Prolactin is an important hormone in reproduction, pregnancy and childbirth. But could it also play a role in the development ...

HDL cholesterol levels not linked to risk of developing movement disorders, suggests research published in the Innovations in ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Segal Trials contributed to the FDA approval of COBENFY™, a new schizophrenia treatment, highlighting their role in advancing ...

An FDA-approved synthetic version of THC (the main ingredient in cannabis) reduces agitation in patients with Alzheimer's ...

The US Food and Drug Administration (FDA) has approved a drug for schizophrenia that is exciting the field with an entirely ...